IRS4 and breast cancer: Further investigating the involvement of IRS4 in human breast cancer, we performed a knockdown of the endogenous IRS4 in these cancer cells and observed a concomitant reduction in PI3K/AKT pathway activation and cell growth (Fig. 6h–j; Supplementary Fig. 7f–i).